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Abstract
The contribution of innate immunity to immunosurveillance of the oncogenic Human Herpes Virus 8 (HHV8) has not been
studied in depth. We investigated NK cell phenotype and function in 70 HHV8-infected subjects, either asymptomatic
carriers or having developed Kaposi’s sarcoma (KS). Our results revealed substantial alterations of the NK cell receptor
repertoire in healthy HHV8 carriers, with reduced expression of NKp30, NKp46 and CD161 receptors. In addition, down-
modulation of the activating NKG2D receptor, associated with impaired NK-cell lytic capacity, was observed in patients with
active KS. Resolution of KS after treatment was accompanied with restoration of NKG2D levels and NK cell activity. HHV8-
latently infected endothelial cells overexpressed ligands of several NK cell receptors, including NKG2D ligands. The strong
expression of NKG2D ligands by tumor cells was confirmed in situ by immunohistochemical staining of KS biopsies.
However, no tumor-infiltrating NK cells were detected, suggesting a defect in NK cell homing or survival in the KS
microenvironment. Among the known KS-derived immunoregulatory factors, we identified prostaglandin E2 (PGE2) as a
critical element responsible for the down-modulation of NKG2D expression on resting NK cells. Moreover, PGE2 prevented
up-regulation of the NKG2D and NKp30 receptors on IL-15-activated NK cells, and inhibited the IL-15-induced proliferation
and survival of NK cells. Altogether, our observations are consistent with distinct immunoevasion mechanisms that allow
HHV8 to escape NK cell responses stepwise, first at early stages of infection to facilitate the maintenance of viral latency, and
later to promote tumor cell growth through suppression of NKG2D-mediated functions. Importantly, our results provide
additional support to the use of PGE2 inhibitors as an attractive approach to treat aggressive KS, as they could restore
activation and survival of tumoricidal NK cells.
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Introduction
Human herpesvirus 8 (HHV8), although known as Kaposi’s
sarcoma-associated herpesvirus (KSHV), is a c herpes virus able to
establish a predominantly latent, life-long infection in host’s
monocytes, dendritic cells (DCs), B lymphocytes, and endothelial
cells. HHV8 is the etiological agent of Kaposi’s sarcoma (KS), a
multifocal angiogenic tumor consisting of spindle-shaped cells of
endothelial origin and infiltrating leukocytes [1,2]. HHV8 lytic
cycle generally occurs following primary infection, and rapidly the
virus enters the latent state. Reactivation leads to the initiation of
the lytic cycle, which is necessary for virus propagation and
survival. Within KS lesions, HHV8 infection is predominantly
latent. KS is the most common neoplasm in untreated AIDS
patients. It also occurs in immunosuppressed organ transplant
recipients, and in some African or Mediterranean populations in
the absence of overt immunosuppression (classical KS). The
marked decline in the incidence of AIDS-KS since the advent of
antiretroviral therapy (ART), and the frequent resolution of
transplant-related KS after reduction of immunosuppression,
highlight the key role of cellular immune responses in the control
of HHV8 infection. We and others recently demonstrated the
crucial role of HHV8-specific cytotoxic T lymphocytes (CTL) in
controlling HHV8 replication, preventing malignancies in latently
infected subjects, and conferring genuine resistance to persistent
infection [3,4]. The multiple mechanisms elaborated by herpes-
viruses to escape immune responses prompted us to explore
further other immune cells involved in the control of HHV8
infection.
NK cells play a key role in early control of viral infections,
through direct lysis of infected cells and secretion of cytokines
controlling viral replication. NK cells also influence specific T-cell
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the establishment of antiviral adaptive responses [5–7]. NK cells
are able to prevent and control the development and dissemina-
tion of tumors [8]. NK cells are therefore likely to represent critical
obstacles HHV8 needs to effectively overcome, not only very early
during infection prior to de novo viral gene transcription, but also
later for the maintenance of persistent infection and establishment
of tumors. NK cell activity is tightly regulated by a fine balance
between activating and inhibitory signals [9]. The latter are mostly
generated by the binding of HLA-1 molecules to the Killer cell
Immunoglobulin-like Receptors (KIRs) and CD94/NKG2A,
which guarantees that healthy self cells will be spared from NK
cell-mediated lysis. Activating receptors, in particular NKG2D
and the natural cytotoxicity receptors (NCR) NKp30, NKp44 and
NKp46, detect the presence of stress-induced or infectious non-self
ligands on abnormal cells. Other receptors, such as CD94/
NKG2C, DNAM-1, NKp80, 2B4 and CD161, can modulate NK
cell effector functions.
HHV8 has exploited several evasion mechanisms to avoid
immune recognition [10]. In particular, the K3 and K5 ubiquitin
ligases, expressed during the early lytic cycle, downregulate HLA-1
molecules on infected cells to avoid virus-specific CTL recognition
[11]. This will at the same time sensitize the virus to missing-self
recognition by NK cells, unless other evasion mechanisms operate
simultaneously. Interestingly, K5 also downmodulates NKG2D
ligands and the ICAM-1 adhesion molecule [12], thus helping
HHV8 to evade NK cell surveillance in the early phase of HHV8
infection before establishing latency, and later during reactivation
and viral replication. NK cells from HIV-viremic AIDS patients
with active KS have a decreased cytolytic capacity against HHV8-
infected body cavity B-cell lymphoma (BCBL-1) cells [13].
However, little is known about how HHV8 by itself, in the
absence of HIV infection, prevents NK cells from killing latently-
infected endothelial cells and KS tumor cells.
To address these questions, we investigated NK cell phenotype
and functions in a large series of HHV8-infected subjects. Our
data revealed substantial alterations in the expression of several
NK cell receptors, even in asymptomatic HHV8 carriers. In
addition, NK cells from patients with active KS showed a
significant decrease of NKG2D expression, which was associated
with impaired cytotoxic capacity. We identified PGE2, a known
tumor-derived inflammatory molecule, as a factor responsible for
NKG2D down-modulation, and for inhibition of IL-15-mediated
activation and survival of NK cells. These observations are
consistent with sequential immunoevasion mechanisms that may
allow HHV8 to escape NK cell recognition at early stages of
infection in order to establish latency, and later to promote tumor
cell growth. Importantly, they give further support to the idea that
PGE2 inhibition based therapy might provide an effective way to
treat the active KS lesions.
Results
HHV8 infection modifies the NK cell phenotype
We addressed the putative influence of HHV8 infection on NK
cell phenotype in a cohort of 70 HHV8-infected individuals,
including 25 asymptomatic carriers (HHV8+ KS2) and 45 KS
patients (HHV8+ KS+) in comparison with 45 HHV8-negative
controls, all sub-grouped according to the presence or absence of
HIV co-infection. To avoid any confounding effect of HIV
replication on the NK cell repertoire, all HIV+ subjects from the
different subgroups were HIV-aviremic, and were matched for
age, CD4 T cell count, CD4 nadir, and duration of disease and
ART.
No gross abnormality in NK cell distribution was observed in
the different patient groups, with levels of total NK cells, and
relative proportions of CD56bright and CD56dim NK cell
subpopulations being comparable to those in controls (Figure 1a).
Accumulation of dysfunctional CD56-negative NK cells was
recently reported in HIV-viremic patients, with suppression of
HIV-viremia upon ART restoring normal proportions of CD56+
NK cells [14–16]. In line with the fact that all study subjects were
HIV-aviremic, we did not observed any abnormal expansion of
CD56-negative NK cells in HHV8-infected patients (Figure S1).
We next analyzed HLA class 1-specific NK cell receptors,
including those belonging to the KIR family (KIR2DL1/S1,
KIR2DL2/L3/S2, KIR3DL1/S1, KIR2DS4), and the HLA-E-
specific CD94/NKG2A and CD94/NKG2C receptors (Figure 1b).
Although large inter-individual variations were observed, the
mean percentage of cells expressing individual KIRs or NKG2A
was overall similar in the different study groups. The fraction of
NKG2C+ NK cells varied within a wide range in infected patients
(,0.1% to 54%), but the difference with uninfected controls was
not statistically significant. CMV seropositivity has been associated
with high frequencies of NKG2C+ NK cells [17,18]. We thus
wondered if the enrichment of NKG2C+ NK cells in some
HHV8-infected patients was related to CMV co-infection.
Notably, 68 out of the 70 HHV8- and/or HIV-infected patients
were CMV IgG positive, and the two remaining CMV IgG-
negative patients had very low NKG2C+ NK cell frequency
(1.56% and 0.25%, respectively). Therefore, it is likely that
previous CMV infection has driven expansion of NKG2C+ NK
cells in HIV- or HHV8-infected patients.
We next studied expression of NK cell receptors that recognize
virus-associated or stressed-induced molecules (Figure 2a). Levels
of NKp30, NKp46 and CD161 were significantly decreased in
HHV8-infected patients compared to controls, whatever the
presence or absence of KS, indicating that HHV8 is able to skew
the NK cell receptor repertoire in otherwise healthy individuals,
before overt tumor transformation. DNAM-1 expression was not
significantly different between the groups. NKp44 was never
detected (not shown). Notably, the profile of NKG2D expression
Author Summary
Natural Killer (NK) cells are part of the innate immune
response against virus infections and tumors. Their
activation is the net result of signals emanating from a
panel of inhibitory and activating receptors recognizing
specific ligands on target cells. Human Herpes Virus 8
(HHV8) is an oncogenic virus responsible of Kaposi
Sarcoma (KS), a multifocal angiogenic tumor. How NK
cells contribute to the control of infection by HHV8
infection and development of KS, is unclear. In this paper,
we show different strategies used by HHV8 to escape NK
cell response. Patients with asymptomatic infection or KS
have down-modulated expression of NKp30, NKp46 and
CD161 receptors. In addition, patients with active KS show
additional down-modulation of the NKG2D activating
receptor, associated with impaired NK-cell cytotoxicity
against target cells. Resolution of KS correlates with
regained NKG2D expression and cytotoxic function. We
present evidence that down-modulation of NKG2D is
mediated by inflammatory prostaglandin E2 (PGE2),
known to be released by KS cells, and show that PGE2
acts by preventing IL-15-mediated activation of NK cells.
These results strongly support the use of PGE2 inhibitors
as an attractive approach to treat active KS.
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were decreased in patients with classical KS (HIV2 HHV8+
KS+), but neither in HIV+ KS+ patients nor in asymptomatic
HHV8-infected subjects (HHV8+ KS2). Because all HIV+ KS
patients were HIV-aviremic upon ART for more than 1 year and
showed complete clinical remission of KS at time of study, we
wondered if NKG2D expression was correlated with the KS
activity. Indeed, NKG2D levels were twofold lower in patients
with active KS (all classical KS) than in patients with resolved
lesions or in healthy controls (Figure 2b,c). By contrast, expression
of other receptors was similarly decreased in KS patients, whatever
disease activity (data not shown).
The variable degrees of NK cell receptor modifications among
patients prompted us to examine whether there was any
correlation between phenotypic changes. We observed highly
significant correlations between expression levels of NKp30,
NKp46 and CD161, the three receptors downmodulated in
asymptomatic HHV8-infected subjects (Figure 3), suggesting that a
common mechanism sustained these alterations. At contrast, there
was no correlation between expression of any of these receptors
and expression of NKG2D.
Taken together, these results show that HHV8 infection
selectively imprints the NK cell receptor repertoire even at an
asymptomatic stage, with a coordinate decrease in NKp30,
NKp46 and CD161 expression. At a more advanced stage, a
specific down-modulation of NKG2D occurs in patients progress-
ing to KS, which is likely mediated by a distinct, KS-specific
mechanism.
Phenotype of HHV8-infected endothelial cells
As a first step to study the molecular interactions underlying NK
cell recognition of infected cells, we analyzed the phenotype of
HHV8-infected endothelial cells, which are considered as one of
the precursors of KS tumor cells. Primary infection of the
microvascular endothelial cell line HMEC with a recombinant
virus, rKSHV.152, expressing the green fluorescent protein (GFP)
and neo (conferring resistance to G418) [19] results in the
establishment of latent HHV8 infection, with a very few
percentage of cells undergoing lytic replication, a situation thought
to mimic in vivo replication. HHV8-infected HMECs exhibited a
two to threefold decreased expression of HLA-1 and ICAM-1
compared to uninfected HMECs (Figure 4a left panel), although
the remaining expression was still very consistent. We thought that
the partial dowmodulation of HLA-1 and ICAM-1 might be
explained by the presence of low levels of early lytic immunoreg-
ulatory proteins such as K3 or K5 in these latently-infected cells, as
previously reported [20,21]. Indeed, qPCR analysis demonstrated
some expression of K3 and K5 mRNAs in infected cells
(Figure 4b). In line with the relatively conserved expression of
HLA-1 molecules, HHV8-infected HMECs showed a consistent
expression of the non-classical HLA class 1b molecule HLA-E,
which is dependent on signal sequences from classical HLA-1
molecules for its stabilization [22]. Because the CMV-encoded
UL40 protein can also contribute a peptide cargo for HLA-E [23],
we searched for potential HLA-E binding peptide motifs in the
HHV8 proteins. We did not find any relevant peptide motif,
indicating that HHV8 by itself is unlikely to stabilize HLA-E
expression (data not shown).
We next analyzed whether HHV8-infected cells expressed
ligands for NK cell receptors. We did not observe any expression
of NKp30 or NKp46 ligands, or of LLT1, the ligand of CD161, on
infected nor uninfected cells. When looking at NKG2D ligands, it
appeared that MICA and MICB were up-regulated on HHV8-
HMECs compared to uninfected cells, while ULBP-1 was not
detected, and ULBP-2 and ULBP-3 were similarly expressed. The
ligands of DNAM-1 (CD155/PVR and CD112/Nectin-2) were
strongly expressed on both uninfected and infected cells, with a
stronger expression of CD155 on HHV8- HMECs.
In attempt to study a model of HHV8-infected cells more
clinically relevant to KS than microvascular endothelial cells, we
generated an immortalized HIV-negative KS-derived cell line.
These SV2G cells exhibited phenotypic characteristics of endo-
thelial cells, as demonstrated by expression of CD146, CD131 and
CD141/thrombomodulin (data not shown). However, HHV8
genome was lost early after the first 2 passages, as in most KS-
derived cell lines [24]. We thus infected SV2G cells in vitro with
rKSHV.152, used above for infecting HMECs. The resulting
HHV8-SV2G cell line showed predominantly latent infection,
with some expression of K3 and K5 mRNAs, like HHV8-HMECs
(Figure 4b). Comparing the phenotype of SV2G and HHV8-
SV2G cells, we observed that, for most markers analyzed,
modifications paralleled those observed in HHV8-HMEC cells,
except for an increased expression of ULBP-2 and ICAM-1 and a
weak but significant detection of NKp30 ligand in HHV8-SV2G
cells compared to uninfected cells (Figure 4a, right panel).
Collectively, these data show that persistently HHV8-infected
cells, which show the same latency program as KS spindle cells,
express a variety of ligands that should allow engagement of
activating NK cell receptors such as NKG2D, DNAM-1 and
NKp30. At the same time however, they show a decreased, but yet
strong expression of HLA-1 molecules that likely protects them
from NK cell lysis.
To determine whether NK cell receptor/ligand interactions
occur at the tumor site, we performed immunohistochemical
staining of KS biopsies. In line with the flow cytometric data on
infected cells, we readily detected expression of HLA-1 and
MICA/B molecules in tumor cells (Figure 4c). We did not observe
any staining using the NKp30-Fc or NKp46-Fc reagents. Ligands
of DNAM-1 and CD161 could not be analyzed due to the lack of
commercially available markers working in paraffin-embedded
tissues. To our surprise, although large inflammatory infiltrates
were observed in most KS samples, we did not detect any CD56-
positive cell, suggesting that NK cells did not reach tumor lesions,
or could not survive in the tumor microenvironment.
NKG2D-mediated NK cell functions are altered in KS
patients
We next evaluated the putative consequences of receptor/ligand
modifications on NK cell functions. NK cells from patients with
active or resolved classical KS and healthy controls were used as
effector cells in CD107a degranulation and intracellular IFNc
production assays in the presence of uninfected or HHV8-infected
KS-derived target cells. As anticipated from the relatively strong
HLA-1 expression on these target cells, NK cell degranulation was
weak and not different between controls and KS patients,
whatever the KS activity (Figure 5a). However, degranulation
Figure 1. NK cell subset distribution in HHV8-infected subjects and controls. Summary graphs of statistical dot plots with medians
(horizontal black bars) in the different study groups showing: (A) the percentage of CD32CD56+ NK cells among PBMCs and the proportion of
CD56bright and CD56 dim among NK cells; (B) the percentage of CD32CD56+ NK cells expressing HLA class I-specific NK cell receptors. P values were
not significant (n.s) after adjustment for multiple comparisons (Kruskall-Wallis test with Dunn’s post test).
doi:10.1371/journal.ppat.1002486.g001
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infected compared to uninfected targets. Whether this was related
to the observed up-regulation of NKG2D, DNAM-1 and NKp30
ligands on infected cells could not be determined. Responses to
PMA/ionomycin, used as positive control, were not impaired in
patient NK cells (mean CD107a+ cells 40.5% compared to 45.1%
in controls), indicating that the granule-exocytosis pathway was
intact. Intracellular IFNc accumulation was almost undetectable
in all conditions, both in controls and patients (data not shown).
We then evaluated the ability of NK cells to recognize K562
target cells, which not only lack HLA-1 molecules, but also express
ligands for NKG2D, DNAM-1, and NKp30 (personal data and
[25]). Compared to healthy controls, patients with resolved
classical KS showed intact NK cell degranulation in spite of
decreased expression of NKp30, NKp46 and CD161. At contrast,
patients with active KS showed significantly impaired NK cell
degranulation (Figure 5b), supporting our hypothesis that the
NKG2D down-modulation observed in these patients might alter
NK cell lytic capacity. Indeed, monoclonal antibody-mediated
masking of NKG2D sharply reduced K562-induced degranulation
of NK cell from healthy controls and resolved KS patients, but had
no effect on NK cells from patients with active KS (Figure 5c).
Moreover, we observed a positive correlation between CD107a
degranulation and expression of NKG2D (Figure 5d), but not of
NKp30 or NKp46. Lastly, comparative analysis of NK cells
obtained before and after successful treatment of active classical
KS in 3 patients showed that regression of KS was associated with
significant restoration of NK cell degranulation, and a parallel
increase in expression of NKG2D, but not of NKp30 and NKp46
(Figure 5e).
Taken together, these results suggest that NKG2D may play an
important role in the control of KS progression in HHV8-infected
individuals.
PGE2 modulates the NK cell phenotype
Shedding of NKG2D ligands constitutes a major counter-
mechanism of tumors to subvert NKG2D-mediated immunosur-
veillance. Thus, soluble MICA released from tumor cells by
proteolytic cleavage drives down-regulation of NKG2D and is
associated with compromised immune response and progression of
disease in cancer patients [26–28]. We quantified soluble MICA in
the serum of KS patients and controls, but found similar low levels
in both groups. In addition, we did not detect soluble MICA in
culture supernatants of HHV8-infected or uninfected cells (data
not shown).
HHV8-infected endothelial cells secrete a variety of pro- and
anti-inflammatory cytokines, growth factors and angiogenic factors
[29–31]. In addition, Cyclooxygenase-2 (COX-2) and its metab-
olite prostaglandin E2 (PGE2), two pivotal proinflammatory
molecules, have been shown to play crucial roles in the
establishment and maintenance of HHV8 latency, and in
inflammatory, angiogenic and invasive events during HHV8
infection [32–34]. In attempt to identify the factors responsible for
phenotypic changes of NK cells in HHV8-infected patients, we
focused on IL-10, TGFb IL-8, VEGF and PGE2, because they
have been involved in the modulation of NK cell functions [35–
40]. Serum levels of IL-10 and TGFb were low and not
significantly different between patients and controls (data not
shown). By contrast, levels of VEGF, IL-8 and PGE2 were
significantly increased in KS patients, particularly in those with
active classical KS (Figure 6a).
To determine if these factors could modify the NK cell
phenotype, control PBMCs were exposed in vitro for 48 h to
VEGF, IL-8, or PGE2, after which NK cell receptor expression
was evaluated (Figure 6b). TGFb used as positive control,
decreased expression of NKG2D and NKp30 as described [35],
but had no significant effect on NKp46, DNAM-1 or CD161. IL-8
and VEGF did not modify the NK cell phenotype. Notably, PGE2
induced a significant decrease of NKG2D expression, but no
reproducible modification of the other NK cell receptors. The
PGE2-induced down-modulation of NKG2D was dose-dependent
(Figure 6c), and was already observed at concentration compara-
ble with those found in the serum of some KS patients. In line with
this observation, NKG2D levels on patient NK cells negatively
correlated with PGE2 serum levels (r=20.70, p 0.01).
Taken together, our results suggest that PGE2 may specifically
alter NKG2D expression on NK cells, thus preventing NKG2D-
Figure 2. Alterations of NK cell receptor expression in HHV8-infected individuals. (A) Summary graphs of statistical dot plots with medians
(horizontal black bars) showing expression (mean fluorescence intensity, MFI) of NKp30, NKp46, CD161, DNAM-1 and NKG2D receptors on gated
CD32CD56+ NK cells in the different study groups. Cells were analyzed on a FACSCalibur flow cytometer. P values,0.05 after adjustment for multiple
comparisons (Kruskall-Wallis test with Dunn’s post test) are indicated. * P,0.01, ** P,0.005, *** P,0.0001. (B) Box and whisker plots showing the
median and 25–75
th percentiles of NKG2D expression in healthy controls (n=35), patients with active KS (n=10, all classical HIV- KS) and patients
with resolved KS (n=35, including 21 classical HIV- KS and 14 HIV+ KS). Horizontal bars indicate the minimal and maximal values. ** P,0.01,
*** P,0.001. (C) Representative flow cytometry analysis in healthy controls (upper panel), asymptomatic HHV8 carriers (middle panel) and patients
with active classical KS (lower panel). Control isotypes are shown as dotted lines.
doi:10.1371/journal.ppat.1002486.g002
Figure 3. Coordinate decrease of NKp30, NKp46 and CD161 expression in HHV8-infected individuals. Positive correlations between the
proportions of NK cells expressing the indicated receptors in HHV8-infected individuals. Spearman rank correlation (r) and P values are indicated.
doi:10.1371/journal.ppat.1002486.g003
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development and/or progression of KS in persistently infected
patients.
PGE2 prevents NK cell responsiveness to IL-15
IL-15 plays a pivotal role in the activation, function and survival
of NK cells. IL-15 is a surface-bound cytokine, presented by
dendritic cells via its high-affinity receptor, IL-15Ra to the
neighboring NK cells that express IL-2/IL-15Rb and c chains.
PGE2 has been reported to suppress cytotoxicity of NK cells
through down-regulation of IL-15Rc [39]. Notably, IL-15 is also a
potent inducer of NKG2D expression [41], and IL-15 signaling
potentiates NKG2D-mediated cytotoxicity of NK cells [42]. To
determine if PGE2 could inhibit IL-15-induced up-regulation of
NKG2D, control PBMCs exposed for 48 h to 5 ng/ml of IL-15 in
the presence or absence of PGE2 (10–1,000 ng/ml), after which
NK cell phenotype was analyzed (Figure 7a). IL-15 alone strongly
up-regulated expression of NKG2D, NKp30 and CD161, but had
no or minor effect on NKp46 and DNAM-1. PGE2, even at low
concentration (10 ng/ml), fully abrogated the IL-15-induced up-
regulation of NKG2D and NKp30, partially inhibited up-
regulation of CD161, and had no effect on expression of NKp46
and DNAM-1.
Because immunochemistry did not detect any CD56-positive
cells within KS lesions, we next wondered if PGE2 could mediate
a defect in survival of NK cells. We analyzed IL-15-induced NK
cell proliferation (expression of Ki67) and survival (expression of
the anti-apoptotic protein Bcl-2), together with surface expression
of IL-15Rb and IL-15Rc (Figure 7b). IL-15Rb was expressed on
almost all NK cells, and was not significantly modified by PGE2.
Conversely, PGE2 fully prevented the IL-15-induced up-regula-
tion of IL-15Rc, as already described. Furthermore, PGE2 was
able to abolish the proliferative and pro-survival responsiveness of
NK cells to IL-15. Staining for annexin V indicated that PGE2, at
the concentrations used (up to 10 mg/ml), did not affect NK cell
viability (not shown).
Taken together, our results indicate that PGE2 inhibits IL-15
signaling in NK cells through down-regulation of IL-15Rc, thus
preventing IL-15 from promoting NKG2D signaling.
Discussion
Infection by the oncogenic virus HHV8 raises issues of control
of latent infection and control of tumor growth. HHV8 must
overcome host’s immune responses not only very early during
infection prior to de novo viral gene transcription, but also after
latent viral gene expression and later on during tumor transfor-
mation. Furthermore, the virus must simultaneously avoid innate
and adaptive responses, using strategies that are sometimes
mutually exclusive. Multiple evasion mechanisms have been
dedicated by herpesviruses to thwart NK cell responses [43–45].
They can downmodulate ligands for NK cell activating receptors,
provide competitors for their ligands, interfere with their
translation, or directly target the activating receptors. It is likely
that several viral inhibitor mechanisms play in concert to
simultaneously or sequentially prevent NK cell activation. Our
study shows for the first time to our knowledge, that distinct NK
cell modifications are observed at the different stages of HHV8
infection, suggesting that selective pressure allows the virus to
evade the successive waves of host immune responses.
First, asymptomatic HHV8 carriers, as well as KS patients,
exhibited significant down-regulation of the NKp30 and NKp46
activating receptors. Whether ligands of these receptors were
expressed on HHV8-infected cells could not be ascertained in the
absence of specific antibodies, although our data suggest that at
least NKp30 ligand was present at the surface of infected cells.
Thus, elimination of NKp30 ligand-expressing cells might be
compromised in case of NKp30 down-modulation on effector
cells. Expression of CD161 was also reduced in asymptomatic
HHV8 carriers. This observation was rather surprising, given
CD161 is described as an inhibitory receptor in NK cells [46,47].
We did not evidence expression of its ligand LLT1 on HHV8-
infected cells, implying that CD161 may not directly participate in
the elimination of these cells. Interestingly, LLT1 is expressed on
TLR-activated DCs and B cells [48], suggesting that it may
contribute to their resistance to NK cell-mediated lysis. The loss of
CD161 might thus result in the accumulation of a population of
NK cells with a lower activation threshold that may be more easily
triggered, which could lead to the elimination of activated DCs
and participate in the defective establishment of antiviral adaptive
responses. Because HHV8 infection of monocytes/macrophages
and B lymphocytes has been demonstrated in KS patients [49,50],
further studies are required to explore LLT1 expression on these
cells, and address whether reduced expression of CD161 modifies
NK-DC interactions during HHV8 infection. Notably, expression
of DNAM-1, another key receptor in NK-cell mediated recogni-
tion of several tumors [51–54], was not significantly altered in
HHV8-infected individuals. Since DNAM-1 ligands were strongly
expressed on HHV8-infected cells, it is possible that at least the
DNAM-1 recognition pathway may operate in NK cells during
HHV8 infection.
Our observation of a co-modulation of NKp30, NKp46 and
CD161 in HHV8 infected subjects suggested us that common
microenvironmental factors, acting early during asymptomatic
stage of infection, might be involved. Multiple inflammatory and
angiogenic factors are produced by HHV8-infected cells. We
could not identify a unique factor capable to induce concomitant
modifications of these receptors. Although IL-8, VEGF and PGE2
were present in high amounts in patient sera, as reported in AIDS-
related KS patients [2,55,56], they had no significant effect on
expression of these NK cell receptors. TGFb down-regulated the
surface expression of NKp30 as reported [35,57], but not that of
NKp46, or CD161. We cannot exclude that intercellular contact
indirectly contribute to alter NK cell phenotype, for instance by
inhibiting the functional maturation of DCs, and therefore
compromising the DC-NK crosstalk. An effect of the microenvi-
ronment on NK cell precursors could also determine their skewed
maturation during HHV8 infection, leading to the prevalent
Figure 4. Expression of ligands for NK cell receptors on HHV8-infected cells. (A) Expression of the indicated ligand was measured by flow
cytometry on uninfected (open histograms) and HHV8-infected (gray histograms) HMEC cells (left panels) and KS-derived cells (right panels). Dotted
lines represent staining with control isotypes. Histograms are representative of 3–6 independent experiments performed in each cell line. B) K3 and
K5 mRNA levels in uninfected or HHV8-infected HMEC and KS-derived cells. Results show the expression level of the K3 and K5 transcripts relative to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA used as endogenous control, and represent the mean of 2 independent experiments. C)
Consecutive sections of paraffin-embedded KS biopsies were stained with antibodies specific for HLA-1 (W6/32), MICA/B (SR99), or isotype control.
Representative staining in 2 patients with classical KS out of 5 studied is shown. Staining with hematoxylin-eosin (HE) shows characteristic fascicles of
spindle-shaped tumor cells forming the walls of slit-like vascular spaces, associated with mononuclear cell infiltrates. Original magnification x10 (Pt1),
x40 (Pt2).
doi:10.1371/journal.ppat.1002486.g004
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PLoS Pathogens | www.plospathogens.org 8 January 2012 | Volume 8 | Issue 1 | e1002486Figure 5. Decreased NK cell lytic capacity in patients with active KS. (A) Comparative analysis of CD107a expression on NK cells from healthy
controls (HC, n=10) and classical KS patients (n=13, including 3 active and 10 resolved KS). Box and whisker plots show the median and 25–75
th
percentiles of CD107a expression, in the absence of stimulation (unst) and after stimulation with SV2G or HHV8-SV2G target cells. Horizontal bars
indicate minimum and maximum values. (B) The capacity to degranulate in the presence of K562 target cells is significantly decreased in patients with
active KS (n=6) compared to healthy controls (HC, n=18) and patients with resolved KS (n=12). (C) K562-induced NK cell degranulation is inhibited
in the presence of anti-NKG2D blocking antibody. Data are mean 6 SEM of results in 3 healthy controls, 3 patients with resolved classical KS and 2
patients with active classical KS. (D) Correlation between the expression level of NKG2D and the respective K562-induced degranulation of NK cells in
15 KS patients (active/resolved). Cells were analyzed on a LSRFortessa flow cytometer. Correlation coefficient (r) and P values are indicated. (E)
Comparative analysis of K562-induced CD107a degranulation and levels of NKG2D, NKp30 and NKp46 in NK cells from 3 patients with active classical
KS analyzed before and one year after successful local treatment.
doi:10.1371/journal.ppat.1002486.g005
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PLoS Pathogens | www.plospathogens.org 9 January 2012 | Volume 8 | Issue 1 | e1002486Figure 6. Effect of PGE2 on NK cell phenotype. (A) Levels of VEGF, TGFb, IL-8 and PGE2 in sera from healthy controls, patients with resolved KS
and patients with active KS. P values,0.05 after adjustment for multiple comparisons (Kruskall-Wallis test with Dunn’s post test) are indicated. (B)
Control PBMCs cells were exposed to IL-8 (100 ng/ml), VEGF (35 ng/ml), TGFb (10 ng/ml) or PGE2 (100 ng/ml) for 48 h, after which expression of the
indicated NK cell receptors was evaluated. Untreated cells are shown as open histograms, and treated cells as gray histograms. Control isotype is
shown as thin lines. (C) Dose-dependent PGE2-mediated down-modulation of NKG2D levels. Data are presented as percent of inhibition of NKG2D
MFI, and indicate the value means from 3 independent experiments.
doi:10.1371/journal.ppat.1002486.g006
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PLoS Pathogens | www.plospathogens.org 10 January 2012 | Volume 8 | Issue 1 | e1002486Figure 7. PGE2-mediated suppression of IL-15-induced NK cell. (A) PGE2 inhibits the IL-15-induced up-regulation of NKG2D and NKp30
expression. Freshly isolated PBMCs were treated for 48h in medium alone, or in the presence of IL-15 alone (5 ng/ml), or IL-15 (5 ng/ml) plus PGE2
(100 ng/ml), and analyzed on a LSRFortessa flow cytometer for surface expression of the indicated receptors. Control isotype is shown as thin lines.
Values inserted in the histograms indicate MFI and are representative of 3 independent experiments. (B) PGE2 inhibits the responsiveness of NK cells
to IL-15. Summarized data show the modification of IL-15Rb, IL-15Rc, Ki67 and Bcl-2 expression in the presence of IL-15 alone (light gray) or with
increasing concentration of PGE2, relative to medium. Results show the fold increased expression of the indicated marker on NK cells cultured for 48h
in the presence of IL-15 and/or PGE2, normalized to the expression on NK cells incubated in medium alone.
doi:10.1371/journal.ppat.1002486.g007
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However, we did not observe any skewing in the distribution of
CD56bright, CD56dim and CD56-negative NK cell subpopula-
tions, as reported in other chronic infections (HIV, HCV). Finally,
the possibility that HHV8 infection of NK cells themselves may
modify their phenotype cannot be excluded so far [58]. Various
leukocyte subsets support HHV8 latency, including B cells,
monocytes, macrophages, DCs and even CD34+ hematopoietic
progenitors [49,50,59–62]. Studies in HHV8-infected NOD/
SCID mice demonstrated the presence of LANA+ NK cells in the
spleens, suggesting that HHV8 can also target NK cells [63], but
this has not been confirmed in the human.
Secondly, in addition to the decreased expression of NKp30,
NKp46 and CD161, patients with active classical KS exhibited
a specific down-modulation of NKG2D and a parallel defect in
NK cell lytic capacity. Resolution of KS after treatment
correlated with restoration of NKG2D levels and NK cell
activity. A decreased NK cell activity was previously reported in
AIDS patients with progressive KS. NK cell function was
restored upon ART treatment, but whether this was only related
to HIV clearance was not determined [13]. Our results indicate
that HHV8 by itself is responsible for the down-modulation of
NKG2D in HIV-negative patients with classical KS. Conse-
quently, NKG2D-mediated NK cell cytotoxicity is hampered. A
small fraction of KS cells express the cascade of lytic cycle genes,
in particular K5, which down-modulates HLA-1, ICAM-1 and
certain MICA/B molecules [12]. Loss of surface MICA/B may
help HHV8 to evade NK cell surveillance in the early phase of
lytic HHV8 infection before establishing latency. This mecha-
nism is clearly not operational in persistently infected KS cells,
which express high levels of MICA/B molecules. Instead, the
decreased expression of NKG2D appears as an efficient mean
for HHV8-infected cells to evade anti-viral immunity and
develop their tumoral program. A similar strategy of decreasing
NKG2D expression is also adopted by another persistent virus,
hepatitis C virus, to evade NK-cell mediated responses in
chronically-infected patients [64 ] .O u rr e s u l t st h u sr e i n f o r c et h e
notion that NKG2D plays an important role not only in control
of viral infections, but also in surveillance of tumor develop-
ment, by protecting the host from tumor initiation and growth
[65–67].
Soluble NKG2D ligands and TGFb are known mechanisms for
down-regulating NKG2D expression [26,27] in some cancer
patients, but were not involved in KS patients. Chronic expression
of NKG2D ligands on tumor tissues also induces the down-
regulation of NKG2D [68]. That MICA was strongly expressed in
situ within KS lesions may sustain the hypothesis that it is an
efficient mechanism to repress antitumor activity by inducing
NKG2D down-modulation on intra-tumoral NK cells. However,
it does not easily explain why NKG2D was reduced on circulating
NK cells. Notably, we observed that PGE2 was able to decrease
NKG2D expression on NK cells in vitro, and PGE2 levels in
patient sera negatively correlated with NKG2D expression on NK
cells.
PGE2 is a major inhibitory factor produced by tumor cells or
their surrounding microenvironment [69]. The rate-limiting
enzyme in PGE2 synthesis is COX-2, which is over-expressed in
many cancers, leading to an over-production of PGE2 often linked
to an adverse clinical outcome [70,71]. COX-2 and PGE2 play
crucial roles in the establishment and maintenance of HHV8
latency program [32]. In addition, HHV8-induced PGE2
regulates VEGF, which controls cell growth, adhesion, angiogen-
esis, proliferation and differentiation. COX-2/PGE2 expression is
induced during the early stages of infection of primary HMEC
cells [32] and in latently-infected human umbilical vein endothelial
cells [34], and abundant COX-2/PGE2 expression is detected in
KS tissues [33,34,72]. We did not detect the presence of PGE2 in
the supernatant of rKSHV.152-infected cells (data not shown),
preventing us from reproducing the effect of synthetic PGE2 on
NK cells with infected cell supernatants. It must be noted that,
although these cells expressed low levels of the early lytic proteins
K3 or K5, our attempts to switch latent infection into lytic cycle
were always unsuccessful. In KS lesions, KSHV-infected cells
show predominantly latent infection, and occasionally undergo
lytic reactivation.
Interestingly, PGE2 was shown to downregulate IL-15Rc chain
on NK cells, thus suppressing IL-15-activated NK cell functions
[39]. IL-15 is critical for NK cell-dependent clearance of several
viral infections, in particular infections by human herpesviruses
[73]. Since IL-15 up-regulates expression of NKG2D, and
potentiates NKG2D signaling through Jak3-mediated phosphor-
ylation of the NKG2D adaptor DAP10 [41,42], it is conceivable
that PGE2 may profoundly affect NKG2D-dependent NK cell
activities. We found that PGE2 not only decreased NKG2D
expression on resting NK cells in vitro, but also fully prevented IL-
15-induced up-regulation of NKG2D, NKp30 and CD161. Thus,
PGE2 overproduction by KS cells may preclude activation of NK
cells during HHV8 infection, and promote a progressive drift
towards hyporesponsive NK cells. We were surprised by the
absence of any CD56+ NK cell within KS lesions, suggesting a
defect in homing or survival of NK cells in the vicinity of tumor
cells. Indeed, we found that PGE2 inhibited IL-15-induced
proliferation and expression of the pro-survival protein Bcl-2 in
NK cells, as previously shown in CD4 T cells [74]. Altogether, our
results strongly suggest that, by inhibiting IL-15-induced prolifer-
ation, activation and NKG2D-mediated function in NK cells,
PGE2 appears as a critical factor in preventing immune
surveillance of KS development in HHV8-infected individuals.
Our results also corroborate recent studies showing the deleterious
effect of PGE2 released from mesenchymal stem cells or
melanoma-derived fibroblasts on IL-2-induced NK cell activation
[37,75].
In conclusion, our study provides additional clues of the
multifactorial complexity of HHV8-host interactions governing
KS progression. In addition to previously reported alterations of
HHV8-specific CD8 T cell responses in KS patients, we now
report how HHV8 stepwise modifies NK cell-mediated activities.
These changes may not only affect the early control of HHV8
infection at an asymptomatic stage, but also preclude efficient
prevention and immunosurveillance of KS. We also provide new
evidence that HHV8 utilizes the inflammatory PGE2 to its
advantage in the KS microenvironment, not only for maintaining
latency as previously reported, but also for inhibiting NK cell
activation, function and survival in response to proinflammatory
cytokines.
These results strongly support the potential for COX-2/PGE2
inhibitors in treating KS, as they could simultaneously control
latency gene expression and chronic inflammation, reduce
angiogenesis and cell adhesion, promote NK cell survival and
restore IL-15-induced priming of NKG2D-mediated cytotoxicity.
Materials and Methods
Ethics statement
The study was performed in accordance with the Declaration of
Helsinki and French legislation, and received approval of the
Saint-Louis Hospital Ethical Committee (P040105). All partici-
pants provided written informed consent.
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The HHV8-infected group consisted of 70 individuals (mean
age 56 years), including 25 asymptomatic HHV8 carriers (HHV8+
KS2) and 45 patients with a history of KS (HHV8+ KS+).
Because HHV8 infection frequently occurs in the context of HIV
infection, patients were sub-classified as follows: HIV2 HHV8+
KS2 asymptomatic carriers (n=10, recruited from a cohort of
ketosis-prone type 2 diabetes patients [76]); HIV+ HHV8+ KS2
asymptomatic carriers (n=15); HIV2 HHV8+ KS+ patients
(n=31 classical KS, including 10 active KS and 21 resolved KS);
HIV+ HHV8+ KS+ patients (n=14 AIDS-related KS, all with
resolved KS following antiretroviral therapy). The HHV8-
negative control group consisted of 45 age-matched subjects,
including 38 healthy blood donor volunteers (HIV2 HHV82),
and 7 HIV+ individuals (HIV+ HHV82). All HIV+ subjects were
on stable antiretroviral therapy and had undetectable HIV load
for at least 1 year before study. In addition, they were matched for
age, CD4 T cell count at time of study, CD4 nadir, duration of
disease and duration of ART in the different subgroups.
Determination of IgG antibodies against latent and lytic HHV8
antigens was performed by indirect immunofluorescence. Cyto-
megalovirus (CMV)-specific IgG were detected by ELISA.
Flow cytometry
Blood samples were processed within 2 h of collection and
PBMCs were separated by Lymphoprep gradient centrifugation
(Abcys). When indicated, NK cells were freshly purified from
PBMCs by negative selection using magnetic microbead separa-
tion (StemCell Technologies) with purity higher than 95%. Cells
were incubated for 20 min at 4uC with combinations of the
following antibodies: FITC-conjugated anti-CD3; PE-conjugated
anti-CD56, anti-NKp30, anti-CD158e1e2 (KIR3DL1/S1), anti-
CD158i (KIR2DS4); APC-conjugated anti-CD56, anti-CD158ah
(KIR2DL1/S1), anti-CD158bbj (KIR2DL2/L3/S2), PE-Cy7-
conjugated anti-CD56, Pacific Blue-conjugated anti-CD3 (all
from Beckman Coulter); PE-conjugated anti-CD3; PercP-conju-
gated anti-CD3, APC-conjugated anti-NKp46, anti-CD161;
FITC-conjugated anti-CD94, anti-DNAM-1 (BD Pharmingen);
PE-conjugated anti-NKG2D (eBioscience); FITC-conjugated anti-
CD122 (IL-15Rb) APC-conjugated anti-NKG2A, anti-NKG2C,
anti-CD132 (IL-15RcR&D Systems). For intracellular detection of
Ki67 and Bcl-2, cells were fixed in 1% formaldehyde, permeabi-
lized with 0.2% saponin and stained with FITC-conjugated anti-
Bcl-2 and PE-conjugated anti-Ki67 (BD Pharmingen). Cells were
analyzed on FACSCalibur or LSRFortessa (BD Biosciences),
collecting a total of 100,000 events in a live gate. Data were
analyzed using FlowJo software.
HHV8-infected cells
SV40-immortalized human microvascular endothelial cells
(HMEC) were infected with rKSHV.152, a recombinant virus
expressing the green fluorescent protein (GFP) and neo (conferring
resistance to G418), and able to establish cells containing only
latent HHV8 [19]. HMEC and HHV8-latently infected HMEC
cells (thereafter called HHV8-HMEC) were cultured in
MCDB131 medium supplemented with 10 ng/ml epidermal
growth factor (EGF) and 1 mg/ml hydrocortisone (Sigma), 10%
fetal calf serum (FCS), 2% glutamine, penicillin (100 U/ml) and
streptomycin (100 U/ml). In addition, HHV8-HMEC medium
contained G418 at 700 mg/ml.
SV2G is an SV40-immortalized HIV-negative KS-derived cell
line. Because HHV8 genome was lost early after the first 2
passages, SV2G was also infected in vitro with rKSHV.152. The
resulting HHV8-SV2G cells line also showed predominantly latent
infection. SV2G cells were cultured in RPMI 1640-10% FCS,
while HHV8-SV2G cells were cultured in 50% HMEC medium/
50% SV2G medium. Cells were seeded at subconfluent density,
and were recovered by trypsine/EDTA treatment. Culture
supernatants were collected and kept frozen. Cell viability
(ViaProbe, Pharmingen) and phenotype were analyzed by flow
cytometry after cell surface staining with antibodies specific for
HLA class I (W6/32), MICA and MICB [77]; ULBP-1, ULBP-2,
ULBP-3, PVR, LLT1 (all from R&D System), Nectin-2 (BD
Pharmingen), HLA-E (clone 3D12, eBioscience) and ICAM-1
(AbD Serotec). Expression of NCR ligands was investigated using
NKp30-Fc and NKp46-Fc fusion proteins (R&D) and FITC-anti-
human Fc antibody (Jackson Immunoresearch). These reagents
were validated for staining NKp30 and NKp46 ligands on K562
and Hela cell lines, previously reported to express these ligands
[25,78,79].
NK cell functional assays
Purified NK cells (10
5 per U-bottom well) were incubated with
target cells at 1:1 effector:target ratio for 6 hr. FITC-conjugated
anti-CD107a (20 mg/mL, BD Biosciences) was added directly.
After 1 hour at 37uC in 5% CO2, brefeldin A (1 mg/ml) and
monensin (6 mg/ml, Sigma) were added for additional 5 hr, and
cells were stained with CD56-APC and CD3-PE antibodies, and
Viaprobe. Where indicated, NK cells were preincubated with
NKG2D blocking antibody (20 mg/ml, Coulter Immunotech) or
isotype control. For intracellular IFNc analysis, cells were fixed
following staining with anti-CD3 and anti-CD56, permeabilized
with 0.2% saponin and stained with IFNc FITC antibody (BD) for
an additional 30 min.
Cell cultures and reagents
Recombinant TGFb, VEGF, IL-8, and IL-15 were purchased
from R&D Systems. PGE2 (Cayman Chemicals) was dissolved at
100 mg/ml in 95% ethanol and further diluted with RPMI 1640.
The final concentration of ethanol had no effect on NK cell
viability and function. ELISA was used to quantify serum IL-8, IL-
10, VEGF and TGFb (R&D Systems), PGE2 (Cayman Chemicals
and soluble MICA ([80]).
Measurement of mRNA levels
Total RNA was extracted from HHV8-infected or uninfected
HMEC and KS-derived cells (RNeasy system; Qiagen) and
retrotranscribed to cDNA with the use of Superscript III reverse
transcriptase and random primers (Invitrogen). For real-time
quantitative polymerase chain reaction, Light Cycler 480 SyBR
Green I Master and Light Cycler 480 detection system (Roche)
were used. The level of K3 and K5 amplified transcripts was
determined using a 25-fold dilution of each cDNA, and
normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA levels. Primers used for quantifying the
expression of K3 and K5 mRNAs were as follows: 59-
gCAAACCCTgTggAAggATA-39 (forward) and 59-AAgCTg-
CAgggTACAAggAA-39 (reverse) for K3; 59-ACCACCACAgA-
CATCAgCAA39 (forward) and 59-gTAgggAAgAggTggggAAC-39
(reverse) for K5.
Immunohistochemistry
Paraffin-embedded KS biopsy samples from 5 patients were
obtained from the Pathology Department. After antigen retrieval
in 10 mM citrate buffer pH 6.0 at 100uC, sections were blocked
with hydrogen peroxide and PBS containing 10% pooled human
AB serum, 1:30 goat serum and incubated at 20uC for 1 hour with
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CD56 (clone 1B6, MBL), or control isotypes, and staining was
visualized by using the Envision+ AEC System (Dako). For
detection of NCR ligands, sections were incubated with NKp30-Fc
or NKp46-Fc fusion proteins (R&D, 8 mg/ml in PBS containing
0.3% normal goat serum), followed by biotin-goat anti-human Fcc
(1:2,000; Jackson Immunoresearch).
Statistical analysis
All statistical tests were performed with Instat 3 (GraphPad
software). Comparisons between two groups were performed using
the Wilcoxon and the Mann-Whitney t tests for paired and
unpaired groups, respectively. Multiple comparison analyses were
performed using Kruskall-Wallis test (non parametric ANOVA)
with Dunn’s multiple comparison test. Two-sided p values less
than 0.05 were considered significant. Correlation analysis was
performed using non parametric Spearman rank correlation.
Accession numbers
Name: NKG2D, Accession number (Swissprot): P26718, Entry
name: NKG2D_HUMAN.
Supporting Information
Figure S1 FACS gating strategy used to identify CD56-negative
NK cells and frequency of this population in the different study
groups. Because our initial staining approach did not include anti-
CD16 mAb for identification of the CD56-negative CD16+ NK
cell populations, we identified NK cells with anti-NKp46 mAb,
and characterized the relative frequencies of CD56-negative cells
out of total NKp46+ NK cells (A). Representative histograms in a
healthy control are shown (B).
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